JP2002509144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002509144A5 JP2002509144A5 JP2000540132A JP2000540132A JP2002509144A5 JP 2002509144 A5 JP2002509144 A5 JP 2002509144A5 JP 2000540132 A JP2000540132 A JP 2000540132A JP 2000540132 A JP2000540132 A JP 2000540132A JP 2002509144 A5 JP2002509144 A5 JP 2002509144A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- formula
- same
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 8
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 150000002596 lactones Chemical class 0.000 description 5
- -1 phenoxy, benzyloxy Chemical group 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- 0 C*1CCClCC1 Chemical compound C*1CCClCC1 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 229910001615 alkaline earth metal halide Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19801646A DE19801646A1 (de) | 1998-01-17 | 1998-01-17 | Substituierte alpha,beta-annellierte Butyrolactone |
| DE19801646.8 | 1998-01-17 | ||
| PCT/EP1999/000132 WO1999036416A1 (de) | 1998-01-17 | 1999-01-12 | SUBSTITUIERTE α,β-ANELLIERTE BUTYROLACTONE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002509144A JP2002509144A (ja) | 2002-03-26 |
| JP2002509144A5 true JP2002509144A5 (https=) | 2006-02-23 |
Family
ID=7854912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000540132A Pending JP2002509144A (ja) | 1998-01-17 | 1999-01-12 | 置換α，β−縮合ブチロラクトン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6462074B1 (https=) |
| EP (1) | EP1047684B1 (https=) |
| JP (1) | JP2002509144A (https=) |
| AU (1) | AU2517299A (https=) |
| DE (2) | DE19801646A1 (https=) |
| ES (1) | ES2185316T3 (https=) |
| WO (1) | WO1999036416A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932621A1 (de) * | 1999-07-13 | 2001-04-26 | Bayer Ag | Neue substituerte alpha, beta-anellierte Butyrolactone |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| US7311701B2 (en) * | 2003-06-10 | 2007-12-25 | Cierra, Inc. | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
| CN101094835B (zh) * | 2004-11-03 | 2011-07-27 | 弗·哈夫曼-拉罗切有限公司 | 二酰胺衍生物 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| AR078171A1 (es) * | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas |
| WO2017223284A1 (en) | 2016-06-23 | 2017-12-28 | University Of Maryland, Baltimore | NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF |
| AU2019392904B9 (en) | 2018-12-07 | 2022-12-22 | University Of Maryland, Baltimore | Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors |
| EP4153303A1 (en) | 2020-05-18 | 2023-03-29 | GEN1E Lifesciences Inc. | P38alpha mitogen-activated protein kinase inhibitors |
| EP4237415A1 (en) | 2020-10-29 | 2023-09-06 | GEN1E Lifesciences Inc. | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
| WO2022204046A1 (en) | 2021-03-23 | 2022-09-29 | Gen1E Lifesciences Inc. | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2605630B1 (fr) * | 1986-10-22 | 1989-06-30 | Roussel Uclaf | Procede de preparation de derives de l'octahydroindole et intermediaires de preparation |
| NZ240921A (en) | 1990-12-12 | 1994-06-27 | Zymogenetics Inc | G protein coupled glutamate receptor (neurotransmitters), recombinant production |
| FR2713064B1 (fr) | 1993-12-03 | 1996-01-12 | Fantino Gilles | Siège dont le dossier articulé fait office de couverture de protection pour l'assise lorsqu'il est rabattu. |
| US5576323A (en) | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| GB9324872D0 (en) | 1993-12-03 | 1994-01-19 | Univ Pasteur | Pharmaceutical compounds |
| GB9325368D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
| GB9325360D0 (en) | 1993-12-10 | 1994-02-16 | Univ Bristol | Organic compounds |
| EP0750621B1 (en) | 1994-03-14 | 1999-07-21 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| AU3414295A (en) | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
| CA2199508A1 (en) * | 1994-09-08 | 1996-03-14 | Darryle Darwin Schoepp | Excitatory amino acid receptor antagonists |
| US5717109A (en) | 1994-09-08 | 1998-02-10 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| WO1996015099A1 (en) * | 1994-11-09 | 1996-05-23 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| US5701168A (en) | 1995-06-29 | 1997-12-23 | Bell Communications Research, Inc. | Inverse twisted and super-twisted nematic liquid crystal device |
| US5945417A (en) | 1995-07-31 | 1999-08-31 | Novo Nordisk | Heterocyclic compounds, their preparation and use |
| WO1997005109A1 (en) | 1995-07-31 | 1997-02-13 | Novo Nordisk A/S | Heterocyclic compounds, their preparation and use |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| GB9605429D0 (en) | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| CN1202167A (zh) * | 1995-11-16 | 1998-12-16 | 伊莱利利公司 | 兴奋性的氨基酸衍生物 |
-
1998
- 1998-01-17 DE DE19801646A patent/DE19801646A1/de not_active Withdrawn
-
1999
- 1999-01-12 EP EP99904767A patent/EP1047684B1/de not_active Expired - Lifetime
- 1999-01-12 ES ES99904767T patent/ES2185316T3/es not_active Expired - Lifetime
- 1999-01-12 DE DE59902921T patent/DE59902921D1/de not_active Expired - Fee Related
- 1999-01-12 AU AU25172/99A patent/AU2517299A/en not_active Abandoned
- 1999-01-12 US US09/600,355 patent/US6462074B1/en not_active Expired - Fee Related
- 1999-01-12 JP JP2000540132A patent/JP2002509144A/ja active Pending
- 1999-01-12 WO PCT/EP1999/000132 patent/WO1999036416A1/de not_active Ceased
-
2002
- 2002-07-25 US US10/206,166 patent/US6723718B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001108591A (ru) | Арилпиперазины и их применение в качестве агентов-ингибиторов металлопротеиназ (ммр) | |
| JP2002509144A5 (https=) | ||
| US4260769A (en) | 5,5-Diphenylhydantoins | |
| JPH04982B2 (https=) | ||
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| KR850008170A (ko) | 피롤로 벤즈 이미다졸의 제조방법과 그들 함유의 약학적 조성물 | |
| EP0539509B1 (en) | 4-alkylimidazole derivatives | |
| RU2004130488A (ru) | Пиримидиновые производные | |
| IE38886L (en) | Quinoline-3-carboxamidotetrazole derivatives | |
| FI94527B (fi) | Analogiamenetelmä lääkeaineena käyttökelpoisen bifenyyli-imidatsopyridiinijohdannaisen valmistamiseksi | |
| ATE448226T1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| KR900011739A (ko) | β-차단/안기 오텐신 Ⅱ 차단 혈압강하제 혼합물 | |
| DE60115465D1 (de) | Immunoregulierende verbindungen, deren derivate und ihre verwendung | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| US4163058A (en) | Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof | |
| IE37795B1 (en) | Pharmacologically active quinaldamide derivatives | |
| EP1857442A3 (en) | Novel antimycobacterial compounds | |
| HUT56343A (en) | Process for producing 3-aminopyrrol derivatives and pahrmaceutical compositions comprising same | |
| DE69217613D1 (de) | Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| KR960701029A (ko) | 하이드록시메틸 푸라잔 카복실산 유도체 및 심장 혈관 질환 치료에서의 이의 용도(Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions) | |
| ATE361925T1 (de) | Pyrrolopyridazin-verbindungen | |
| JP3131209B2 (ja) | 抗癲癇ピラゾロピリジン類 | |
| KR900001701A (ko) | 이미다조피라졸 유도체의 진통제 및 항염제로서의 용도 | |
| MC2225A1 (fr) | Derives de diamine | |
| JP2828686B2 (ja) | １，３―オキサジン―４―オン化合物およびその用途 |